Abstract
BackgroundRecently, the lymphocyte-to-monocyte ratio (LMR) has been reported to be a prognostic factor in multiple malignancies. The current study was designed to assess the prognostic value of pretreatment LMR in gastric cancer (GC). MethodsMEDLINE, EMBASE, Cochrane, and CNKI databases were searched until April 2017. Eligible articles were defined as studies assessing the prognostic role of pretreatment LMR in GC. Pooled hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were calculated using fixed-effects or random-effects models. ResultsA total of six studies comprising 4908 patients were included in the study. Pooled results showed that low LMR was significantly associated with decreased OS (HR: 0.66, 95% confidence interval [CI]: 0.54–0.82, p < .001), but not with poor DFS/RFS (HR: 0.71, 95% CI: 0.38–1.32, p = .004). The unfavorable prognostic impact of low LMR on OS was observed in patients of different disease stages and cut-off values. Moreover, low LMR was significantly related to age (>median), gender (male), CEA (>5 ng/ml), tumor size (>3 cm), TNM stage (III-IV), lymph node metastasis, and distant metastasis. ConclusionsLow pretreatment LMR may be a significant prognostic biomarker for poor OS in patients with GC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
